Browse Category

NASDAQ:SAVE News 13 December 2025

Spirit Airlines Bankruptcy: Dec. 13 Funding Deadline Fuels Shutdown Fears as American Airlines Expands at Chicago O’Hare

Spirit Airlines Bankruptcy: Dec. 13 Funding Deadline Fuels Shutdown Fears as American Airlines Expands at Chicago O’Hare

Updated: December 13, 2025 — Spirit Airlines is facing a pivotal Chapter 11 milestone today that could determine whether the ultra-low-cost carrier can keep flying without disruption into the peak holiday travel stretch. Rival airlines are reportedly preparing contingency plans for a potential Spirit shutdown, even as Spirit insists flights are operating normally. At the same time, American Airlines emerged as an unexpected—and increasingly visible—player in Spirit’s bankruptcy orbit, buying Spirit’s O’Hare gates and formally joining the bankruptcy docket to receive court filings.Reuters+ 5The Air Current+ 5DRY+ 5 What’s happening today: the Dec. 13 Spirit Airlines funding milestone The immediate

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Go toTop